respiratory syncytial virus (RSV)

(Adobe Stock)
January 16, 2026

Vanderbilt Health team finds potent antibody that neutralizes two dangerous viruses

The single administration of an antibody that provides cross-protection against both RSV and hMPV infection could provide logistical and economic advantages over the need to develop and administer multiple virus-specific monoclonal antibodies.

By Bill Snyder
Cryogenic electron microscopy (cryo-EM) resolution of the structure of a respiratory syncytial virus fusion protein (shades of pink) bound to fragments of two antibodies (dark/light and blue/green) designed by the researchers’ protein language model, MAGE.
November 4, 2025

AI can speed antibody design to thwart novel viruses: study

While the study focused on development of antibody therapeutics against existing and emerging viral threats, the implications of the research are much broader.

By Bill Snyder
November 3, 2025

Prescribing with purpose

A Vanderbilt University Medical Center study finds unnecessary antibiotic prescriptions in hospitalized children and highlights opportunity for antibiotic stewardship.

By Chelsea N. Campbell
(Adobe Stock)
August 30, 2025

One shot of RSV vaccine effective against hospitalization in older adults for two seasons

RSV causes substantial seasonal illness during fall and winter in the U.S., with an estimated 100,000-150,000 hospitalizations and 4,000-8,000 deaths.

By Craig Boerner
June 17, 2025

VUMC-led research a step closer to understanding, preventing asthma 

“Findings from this study indicate that children who develop wheezing have different airway characteristics early in life, even before they develop asthma,” said Tina Hartert, MD, MPH.

By Bill Snyder
May 8, 2025

Newer preventive options helping reduce RSV-associated hospitalization rates among infants

For decades no effective preventive options existed, and the tools now exist to prevent severe disease.

By Jessica Pasley